09Nov 2023
Sun Pharma Gets CDSCO Nod To Manufacture, Market FDC Silodosin JP Plus Tadalafil

Sun Pharma Gets CDSCO Nod To Manufacture, Market FDC Silodosin JP Plus Tadalafil

The Central Drug Standard Control Organisation (CDSCO) has permitted Sun Pharma to manufacture and market the fixed-dose combination Silodosin JP plus Tadalafil. The firm presented its proposal and the Phase Ill CT report before the committee. Silodosin is an alpha-blocker that is used to improve urination in men with benign prostatic hyperplasia (enlarged prostate). Tadalafil is a phosphodiesterase five inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.

  • #family health

Like

Save

Share